10-K: Alto Neuroscience Reports Mixed Clinical Results, Secures Funding

Alto Neuroscience's 2025 annual report highlights progress in its precision psychiatry pipeline with new funding, despite a setback in its ALTO-100 MDD trial.

Summary

• Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through its proprietary Precision Psychiatry Platform, which uses neurobiology and machine learning to identify brain-based biomarkers for personalized treatment.
• The company's pipeline includes seven clinical-stage assets targeting major depressive disorder (MDD), bipolar depression (BPD), treatment-resistant depression (TRD), schizophrenia, and Parkinson's disease.
• Net losses for the year ended December 31, 2025, were $63.2 million, an increase from $61.4 million in 2024, with an accumulated deficit of $201.6 million.
• Cash, cash equivalents, and restricted cash increased to $177.0 million as of December 31, 2025, from $168.7 million in 2024, primarily due to financing activities.
• Research and development expenses decreased slightly to $45.6 million in 2025 from $47.0 million in 2024, influenced by varying program stages and new acquisitions.
• General and administrative expenses decreased to $20.7 million in 2025 from $21.6 million in 2024, mainly due to reduced consulting and professional fees.
• The company completed a private placement in October 2025, raising approximately $49.7 million net, by issuing common stock and pre-funded warrants.
• An amendment to the K2 Loan Agreement in January 2025 increased the maximum available term loans to $75.0 million, with $20.0 million funded, but a $30.0 million second tranche expired undrawn.
• A $4.0 million portion of the K2 loan was converted into 828,860 shares of common stock in November 2025 at $4.83 per share.
• The Wellcome Trust Limited provided a convertible loan of up to approximately $11.7 million in July 2024 to support the ALTO-100 BPD trial, with $2.0 million drawn by December 31, 2025, and an additional $3.0 million available upon milestone achievement.
• ALTO-207 (TRD) is expected to initiate a Phase 2b trial in the first half of 2026 and a Phase 3 trial by early 2027, following positive Phase 2a results from its prior owner.
• ALTO-300 (MDD) is in an ongoing Phase 2b trial, with topline data expected in mid-2026, and a positive interim analysis in February 2025 recommended increasing the target biomarker-positive population to 200 patients.
• ALTO-100's Phase 2b study in MDD did not meet its primary endpoint in October 2024, but a clinically meaningful signal in the adjunctive subgroup and biomarker enrichment in compliant patients support its continued development in BPD.
• ALTO-101 (CIAS) completed enrollment for its Phase 2 proof-of-concept trial, with topline data expected around the end of Q1 2026, and received FDA Fast Track designation in October 2025.
• ALTO-203 (MDD with anhedonia) completed an exploratory Phase 2 POC trial in June 2025, identifying a patient selection biomarker and showing effects on attention and wakefulness, but experienced a higher-than-expected placebo response on subjective measures.
• The company is subject to a putative class action lawsuit and a consolidated stockholder derivative action filed in July 2025, alleging securities law violations related to its IPO and ALTO-100 disclosures, which the company intends to dismiss.
• The company believes its existing cash and cash equivalents, along with anticipated Wellcome proceeds, will fund operations into 2028.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing with mixed sentiment. While significant financing was secured and several pipeline assets show promise with positive interim or prior trial data and a Fast Track designation, the failure of ALTO-100's MDD trial primary endpoint and the undrawn K2 loan tranche represent notable setbacks and increased cash burn.

Positives

• ALTO-207 (TRD) showed statistically significant and clinically meaningful improvements in depression symptoms in a prior Phase 2a trial, with a mean dose of 4.1mg/day achieved and 67% of patients reaching the highest allowed dose of 5mg/day, demonstrating good tolerability.
• ALTO-300 (MDD) demonstrated robust clinical response in biomarker-positive patients in its completed Phase 2a trial, with significantly more responders (47% vs. 28% at week 4, 58% vs. 34% at week 6, 62% vs. 48% at week 8) compared to patients without the biomarker, and was well tolerated with no liver function test elevations.
• A favorable interim analysis for the ALTO-300 Phase 2b trial in MDD recommended continuing the study and increasing the target biomarker-positive population from 150 to 200 patients, improving the overall probability of success.
• ALTO-101 (CIAS) received FDA Fast Track designation in October 2025, which may expedite its development and review process.
• The transdermal formulation of ALTO-101 achieved greater systemic drug exposure than oral administration in a Phase 1 trial while demonstrating a reduction in typical class-related adverse events, supporting its unique delivery approach.
• An independent replication study in September 2025 successfully replicated EEG biomarkers in schizophrenia, supporting the use of this objective, brain-based measurement for ALTO-101.
• ALTO-208 (Parkinson's disease) demonstrated a significantly higher mean tolerated dose (exceeding standard pramipexole) and favorable safety/tolerability in a completed Phase 2a trial.
• The company successfully completed a private placement in October 2025, raising approximately $49.7 million in net proceeds, strengthening its financial position.
• The K2 Loan Agreement was amended in January 2025, extending the maturity date to January 1, 2029, and increasing the maximum available term loans to $75.0 million.
• The Wellcome Trust Limited provided a convertible loan of up to approximately $11.7 million to support the ALTO-100 BPD clinical trial, with $3.0 million in additional milestones achieved as of December 31, 2025.
• The company's existing cash and cash equivalents, combined with anticipated Wellcome proceeds, are projected to fund operating expenses and capital expenditure requirements into 2028.

Negatives

• The company incurred increased net losses, rising to $63.2 million in 2025 from $61.4 million in 2024, and has an accumulated deficit of $201.6 million.
• Net cash used in operating activities increased to $51.8 million in 2025 from $47.4 million in 2024.
• The ALTO-100 Phase 2b study in MDD did not meet its primary endpoint in October 2024, indicating a failure in that specific trial design and population.
• The second tranche of $30.0 million in term loans under the Amended K2 Loan Agreement expired in December 2025 without being drawn, limiting access to potential capital.
• ALTO-203's exploratory Phase 2 POC trial observed a higher-than-expected placebo response on subjective Bond & Lader measurements, obscuring significant separation of subjective effects from ALTO-203.
• The company is currently subject to a putative class action lawsuit and a consolidated stockholder derivative action alleging securities law violations and breach of fiduciary duty, which could incur significant legal expenses and divert management attention.
• Other income, net, decreased significantly to $3.1 million in 2025 from $7.2 million in 2024, primarily due to lower interest income, higher interest expense, and debt extinguishment costs.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no history of commercializing products, making its future viability uncertain.
• Preclinical and clinical development is a lengthy, expensive, and uncertain process, with a high rate of failure, and earlier trial results may not predict future outcomes.
• The company will require substantial additional financing to achieve its goals, and failure to obtain capital on acceptable terms could delay or terminate product development and commercialization efforts.
• Reliance on the unproven biomarker-driven Precision Psychiatry Platform carries the risk that the FDA may not agree with this approach, or that companion diagnostics cannot be successfully developed and approved, materially harming the business.
• Even if necessary studies are completed, the marketing approval process is expensive, time-consuming, and uncertain, potentially preventing or delaying commercialization.
• Approved products may fail to achieve market acceptance by physicians, patients, and third-party payors, limiting revenue generation and profitability.
• Successful commercialization depends on governmental authorities and health insurers establishing adequate coverage, reimbursement levels, and favorable pricing policies, which may not be achieved.
• The company's business depends on the success of its product candidates; failure or significant delays in commercialization would materially harm the business.
• Reliance on internal clinical development expertise and external vendors/CROs means non-compliance, missed deadlines, or ineffective trial execution could delay regulatory approval.
• The company is subject to securities class action litigation and derivative claims, which are expensive, time-consuming, and can damage reputation and divert management attention.
• The terms of the Amended Loan Agreement and Convertible Grant Agreement place restrictions on operating and financial flexibility and may cause dilution to stockholders.
• Competitive products or technologies developed more rapidly or proving more effective/safer could reduce or eliminate commercial opportunities for the company's product candidates.
• Dependence on key management and scientific personnel means the inability to retain or recruit such individuals would harm the business.
• Inability to obtain and maintain sufficient intellectual property protection, or if existing patents are challenged, invalidated, or expire, could allow competitors to commercialize similar products.
• Rights to develop and commercialize product candidates are largely subject to third-party licenses (e.g., Stanford, Sanofi, MedRx), and failure to comply with obligations could lead to loss of these critical rights.
• Patent terms may be inadequate to protect the competitive position for a sufficient amount of time, allowing generic competition after expiration of regulatory exclusivities.
• Conflicts with licensors or collaborators could delay or prevent development/commercialization.
• Failure or perceived failure to comply with evolving data privacy and security laws, regulations, and contractual obligations could harm the business, increase costs, and limit product use.
• Operations concentrated in California expose the company to risks from natural disasters like wildfires and earthquakes, potentially disrupting business continuity.
• Projections regarding market opportunities for product candidates may be inaccurate, leading to smaller-than-estimated actual markets.
• Health pandemics or epidemics could cause significant disruptions to operations and those of third-party partners.
• The company's ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes (Sections 382 and 383 of the Code).
• Unstable economic and market conditions, including inflation and rising interest rates, may adversely affect the business, financial condition, and stock price.
• As a public company, the company incurs increased costs and management must devote substantial time to new compliance initiatives and corporate governance practices.
• Failure to establish and maintain effective internal control over financial reporting could adversely affect the business and investor confidence.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult and limit stockholder influence.

Future Outlook

The company anticipates incurring substantial and increasing losses for the foreseeable future as it advances its product candidates through clinical development, seeks regulatory approvals, builds commercial capabilities, and expands its pipeline. It expects to require substantial additional funding to complete clinical development and commercialization. The company believes its existing cash and cash equivalents, combined with anticipated proceeds from the Wellcome Convertible Grant Agreement, will be sufficient to fund operating expenses and capital expenditure requirements into 2028. Future capital requirements are highly dependent on the scope, timing, and success of clinical trials, regulatory review, manufacturing, and market acceptance. The company plans to continue evaluating ALTO-203 for the best indication to pursue and will provide further details on planned development in the future.

Management Comments

• Management believes that the profile of ALTO-207 will enable higher dosing of pramipexole while mitigating the significant rates of nausea and vomiting that have limited its use for depression.
• Management believes the neuropsychiatry domain expertise leveraged to develop the Platform provides a distinct advantage in the ability to discover and develop biomarkers that are highly relevant to underlying brain circuit function.
• Management believes the opportunity across the portfolio represents a potential to impact over 25 million patients in the United States alone.
• Management believes the clinically meaningful signal in the adjunctive subgroup of the ALTO-100 MDD trial, combined with the evidence of biomarker enrichment in the compliant subset of patients, supports continuing the Phase 2b trial of ALTO-100 as an adjunctive treatment in BPD.
• Management believes the evidence across analyses of the ALTO-100 Phase 2b MDD trial broadly supports the enrichment approach as having the potential to identify patients that could demonstrate a better response to treatment.
• Management believes that its existing financial resources are sufficient to continue operating activities at least one year past the issuance date of these consolidated financial statements (as of March 16, 2026).
• Management believes that its existing cash and cash equivalents, together with the anticipated proceeds under the Convertible Grant Agreement with Wellcome, will be sufficient to fund operating expenses and capital expenditure requirements into 2028.

Industry Context

StockSavvy.ai notes that Alto Neuroscience operates in the highly challenging neuropsychiatry drug development sector, which historically has a low likelihood of approval from Phase 1 (7.3% in psychiatry, 6.2% in neurology). The company's precision psychiatry approach, leveraging biomarkers and machine learning, aims to differentiate itself from traditional 'all-comer' CNS drug development, a strategy that, if successful, could significantly improve success rates in a field plagued by high placebo effects and subjective endpoints. The FDA's Fast Track designation for ALTO-101 for CIAS indicates regulatory recognition of the unmet need in this area. The competitive landscape includes major biopharmaceutical companies with greater resources, suggesting Alto's success will hinge on its ability to validate its platform and achieve superior efficacy and safety profiles in stratified patient populations.

Comparison to Industry Standards

• ALTO-207's prior Phase 2a results, demonstrating statistically significant and clinically meaningful improvements on the MADRS, compare favorably to the large reduction in symptoms (Cohens d=0.87) seen with pramipexole augmentation in the PAX-D study, while aiming to mitigate the high adverse event rates associated with pramipexole alone.
• ALTO-300 (agomelatine) has demonstrated similar all-comer efficacy and favorable tolerability compared to other adjunctive treatments in Europe and Australia, with no difference in dropout due to adverse events, unlike many antipsychotics. It has also shown better treatment of anhedonia symptoms compared to SSRIs/SNRIs in third-party clinical trials.
• The observed low rates of liver function test elevations with the 25mg dose of ALTO-300 are a positive differentiator, as a published meta-analysis of over 58,000 patients demonstrated agomelatine is not associated with elevated AST or ALT, unlike certain other commonly used antidepressants.
• The 7.3% and 6.2% likelihood of approval from Phase 1 in psychiatry and neurology, respectively, highlights the significant challenge Alto faces, making its biomarker-driven approach a potential industry disruptor if it can consistently improve success rates beyond these low benchmarks.
• The company's ability to achieve a mean tolerated dose of 4.1mg/day for ALTO-207 in Phase 2a, with 67% of patients reaching 5mg/day, is a notable improvement over real-world data where achieving doses above 1mg/day of pramipexole is challenging.

Management Changes

Corporate Governance

Legal Proceedings

• On July 21, 2025, a putative class action lawsuit was filed against the company, certain executive officers, and current/former directors in the U.S. District Court for the Northern District of California (Case No. 3:25-cv-06105). The amended complaint, filed January 23, 2026, alleges violations of the Securities Act related to the company's IPO in February 2024 and violations of the Exchange Act thereafter, claiming materially false and misleading statements and omitted material facts about ALTO-100's prospects. The plaintiff seeks unspecified damages, interest, fees, and costs. The company believes these allegations lack merit and intends to move to dismiss.
• A consolidated stockholder derivative action, captioned In re Alto Neuroscience, Inc. Derivative Litigation, Lead Case No. 5:25-cv-07144-NW, was filed on behalf of the company against certain executive officers and current/former directors. This action alleges breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and federal securities law violations, arising from the same factual allegations as the class action. This action was stayed on January 14, 2026, pending resolution of the motion to dismiss in the securities class action. The company believes these claims lack merit.
• The company has not recorded a liability related to these lawsuits, as it does not believe an unfavorable outcome is probable or estimable at this time.

Related Party Transactions

• The company issued an aggregate of 104,348 shares of common stock to Stanford University, the UT Board, and five inventors (including CEO Amit Etkin) as partial consideration for the Stanford License Agreement. Stanford also purchased an aggregate of 627,189 shares of Series Seed and Series A convertible preferred stock through a participation right that terminated upon the IPO.
• The K2 Loan Agreement and its amendment involve K2 HealthVentures LLC as a lender and administrative agent. The lender converted $4.0 million of its outstanding loan balance into 828,860 shares of the company's common stock in November 2025. The lender also holds warrants to purchase common stock and has an option to convert an additional $5.0 million of the loan into common stock.
• The Convertible Grant Agreement is with The Wellcome Trust Limited, which provided an unsecured convertible loan of up to approximately $11.7 million. Wellcome has the right to convert some or all of the loan into common stock under certain conditions.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financings, warrant exercises, and loan conversions. Stock price volatility is a risk due to clinical trial outcomes, competition, and litigation. Anti-takeover provisions may limit opportunities for a premium in an acquisition. The ongoing lawsuits could negatively impact stock price and reputation.
• Employees: Headcount reduction in May 2025 impacted some employees. The company's success depends on attracting and retaining highly qualified management, clinical, and scientific personnel. Stock-based compensation plans are in place to incentivize employees.
• Customers (future patients): The company's mission is to provide personalized and highly effective treatment options for high-need therapeutic areas, potentially offering significant improvements over current standard-of-care medications if product candidates are approved and gain market acceptance.
• Creditors (K2 HealthVentures, Wellcome Trust): The company's obligations under loan and grant agreements are secured by assets (K2) or convertible (Wellcome), with specific repayment and conversion terms. Failure to meet financial covenants or achieve milestones could trigger events of default.
• Suppliers and Manufacturers: Reliance on third-party CMOs and suppliers for drug substances and products exposes the company to supply chain risks, including potential disruptions, quality issues, and increased costs, which could impact clinical trial timelines and commercialization.

Next Steps

• Initiate the planned Phase 2b trial for ALTO-207 in TRD in the first half of 2026.
• Initiate a Phase 3 trial for ALTO-207 by early 2027, following Phase 3 readiness work and FDA alignment.
• Report topline data from the ALTO-300 Phase 2b trial in MDD in mid-2026.
• Report topline data from the ALTO-101 Phase 2 proof-of-concept trial around the end of the first quarter of 2026.
• Report topline data from the ALTO-100 Phase 2b trial in BPD in the second half of 2026.
• Continue to evaluate the best indication to pursue with ALTO-203 and provide further details on planned development in the future.
• Plan the next phase of clinical development for ALTO-202.
• Continue to pursue additional funding through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and other similar arrangements.
• Work closely with the FDA and comparable foreign regulatory authorities to perform requisite scientific analyses and evaluations for regulatory approval of product candidates.
• Monitor equity movement and its impact on the utilization of Net Operating Losses (NOLs) and credits.

Key Dates

Recommendation

Alto Neuroscience presents a high-risk, high-reward profile typical of a clinical-stage biopharmaceutical company. The company has a promising biomarker-driven platform and several pipeline assets with positive early-stage data and a Fast Track designation for ALTO-101. However, the failure of the ALTO-100 MDD trial's primary endpoint, despite mitigating factors, is a significant setback. The company's increased net loss and cash burn, coupled with the undrawn K2 loan tranche, highlight ongoing financial challenges and the need for substantial future capital. While recent financing has improved liquidity into 2028, the presence of ongoing securities litigation adds further uncertainty. A 'hold' recommendation is appropriate given the mixed clinical results, the inherent risks of drug development in neuropsychiatry, and the ongoing legal proceedings, balanced against the potential of its precision psychiatry platform and other promising pipeline candidates.

Keywords

Precision Psychiatry, Neuroscience, Biopharmaceutical, Clinical-stage, Biomarkers, EEG, Major Depressive Disorder, MDD, Bipolar Depression, BPD, Treatment Resistant Depression, TRD, Schizophrenia, Cognitive Impairment Associated with Schizophrenia, CIAS, Parkinson's Disease, ALTO-207, ALTO-300, ALTO-100, ALTO-101, ALTO-203, ALTO-202, ALTO-208, Drug Development, Clinical Trials, FDA Fast Track, SEC Filing, 10-K, Capital Raise, Convertible Loan, Warrants, Intellectual Property, Pharmaceuticals